APA (7th ed.) Citation

Bae-Jump, V. L., Sill, M. W., Gehrig, P. A., Merker, J. D., Corcoran, D. L., Pfefferle, A. D., . . . Aghajanian, C. (2025). A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study. Gynecologic Oncology, 195, 66. https://doi.org/10.1016/j.ygyno.2025.03.003

Chicago Style (17th ed.) Citation

Bae-Jump, Victoria L., et al. "A Randomized Phase II/III Study of Paclitaxel/carboplatin/metformin Versus Paclitaxel/carboplatin/placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer: An NRG Oncology/GOG Study." Gynecologic Oncology 195 (2025): 66. https://doi.org/10.1016/j.ygyno.2025.03.003.

MLA (9th ed.) Citation

Bae-Jump, Victoria L., et al. "A Randomized Phase II/III Study of Paclitaxel/carboplatin/metformin Versus Paclitaxel/carboplatin/placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer: An NRG Oncology/GOG Study." Gynecologic Oncology, vol. 195, 2025, p. 66, https://doi.org/10.1016/j.ygyno.2025.03.003.